These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25001387)

  • 21. Cancer research: Open ambition.
    Maxmen A
    Nature; 2012 Aug; 488(7410):148-50. PubMed ID: 22874946
    [No Abstract]   [Full Text] [Related]  

  • 22. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
    Borbely G; Haldosen LA; Dahlman-Wright K; Zhao C
    Oncotarget; 2015 Oct; 6(32):33623-35. PubMed ID: 26378038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells.
    Yang S; Lee JY; Hur H; Oh JH; Kim MH
    BMB Rep; 2018 Sep; 51(9):450-455. PubMed ID: 29804556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer.
    Murphy LC; Leygue E; Niu Y; Snell L; Ho SM; Watson PH
    Br J Cancer; 2002 Dec; 87(12):1411-6. PubMed ID: 12454770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. When are the BET factors the most sensitive to bromodomain inhibitors?
    Khochbin S
    Transcription; 2013; 4(2):54-7. PubMed ID: 23412362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
    Cortez V; Mann M; Tekmal S; Suzuki T; Miyata N; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Vadlamudi RK
    Breast Cancer Res; 2012 Jul; 14(4):R108. PubMed ID: 22812534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic biomarker screening by FLIM-FRET for combination therapy in ER+ breast cancer.
    Liu W; Cui Y; Ren W; Irudayaraj J
    Clin Epigenetics; 2019 Jan; 11(1):16. PubMed ID: 30700309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
    Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
    BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure.
    Qi J
    Cold Spring Harb Perspect Biol; 2014 Dec; 6(12):a018663. PubMed ID: 25452384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance.
    Zou JX; Duan Z; Wang J; Sokolov A; Xu J; Chen CZ; Li JJ; Chen HW
    Mol Cancer Res; 2014 Apr; 12(4):539-49. PubMed ID: 24391143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
    Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
    Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
    Morrison AJ; Herrera RE; Heinsohn EC; Schiff R; Osborne CK
    Mol Endocrinol; 2003 Aug; 17(8):1543-54. PubMed ID: 12730327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
    Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.
    Cheng R; Liu YJ; Cui JW; Yang M; Liu XL; Li P; Wang Z; Zhu LZ; Lu SY; Zou L; Wu XQ; Li YX; Zhou Y; Fang ZY; Wei W
    Oncotarget; 2017 May; 8(18):30252-30264. PubMed ID: 28415819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
    Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
    Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.
    Lochrin SE; Price DK; Figg WD
    Cancer Biol Ther; 2014; 15(12):1583-5. PubMed ID: 25535892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
    Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
    Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins.
    Tryndyak VP; Kovalchuk O; Pogribny IP
    Cancer Biol Ther; 2006 Jan; 5(1):65-70. PubMed ID: 16322686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
    Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
    Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.